Literature DB >> 3806159

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

G M Clark, G W Sledge, C K Osborne, W L McGuire.   

Abstract

Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survival

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806159     DOI: 10.1200/JCO.1987.5.1.55

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  73 in total

1.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.

Authors:  Walter Schippinger; Peter Regitnig; Nadia Dandachi; Klaus-Dieter Wernecke; Thomas Bauernhofer; Hellmut Samonigg; Farid Moinfar
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

2.  Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.

Authors:  S Yamasaki; T Okino; N Kan; K Satoh; K Mise; Y Teramura; T Harada; H Kodama; T Hori; K Ohgaki
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].

Authors:  P Mainka; S Kahlert; T Kirchner; D Mayr; J Diebold
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 4.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Luminal breast cancer metastasis is dependent on estrogen signaling.

Authors:  Vidya Ganapathy; Whitney Banach-Petrosky; Wen Xie; Aparna Kareddula; Hilde Nienhuis; Gregory Miles; Michael Reiss
Journal:  Clin Exp Metastasis       Date:  2012-03-17       Impact factor: 5.150

6.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.

Authors:  E A Stadtmauer; D E Tsai; C J Sickles; R Mick; S M Luger; D L Porter; P A Mangan; L M Schuchter; S J Schuster; E Y Loh; D A Magee; R A Sachs; M E Wall; J Moore; G P Buzby; E Zaleta; M Kamoun; L E Silberstein
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

8.  Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer.

Authors:  C Dittrich; R Jakesz; K Pirich; L Havelec; G Steger; O Schlappack; R Kolb; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

9.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Authors:  Brunilde Gril; Diane Palmieri; Julie L Bronder; Jeanne M Herring; Eleazar Vega-Valle; Lionel Feigenbaum; David J Liewehr; Seth M Steinberg; Maria J Merino; Stephen D Rubin; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

10.  Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.

Authors:  S Yamasaki; N Kan; T Harada; Y Ichinose; Y Moriguchi; L Li; T Sugie; H Kodama; K Satoh; K Ohgaki
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.